Animal Cancer Models in Anticancer Drug Discovery and Development

  • Francis Lee
  • Roberto Weinmann


The prevention and treatment of cancer continues to pose great challenges to modern medical science. Long dreaded, cancer remains one of most lethal diseases in the United States and is poised to overtake heart diseases as the most common cause of death in the very near future [1]. Despite great advances over the last 50 years in our understanding of the cause (the genetics of cancer) and pathological progression (the physiology of cancer), efforts in the clinic to effectively control the disease have met with uneven successes in prolonging patients survival, ranging from the highly effective (in the treatment of even advanced stages of choriocarcinoma, testicular cancers, and some lymphomas), to the partially effective (when used as an adjuvant to surgery in the early stages of some common carcinomas of adults), to the modest at best (in the treatment of the most common advanced stages adult solid malignancies). In recent years, through unprecedented collaborative...


Acute Lymphoblastic Leukemia Chronic Myelogenous Leukemia Human Tumor Xenograft Taxane Resistance Antitumour Efficacy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
  2. 2.
    Kola, I. and J. Landis (2004). “Can the pharmaceutical industry reduce attrition rates?” Nature Reviews. Drug Discovery 3(8): 711–716.PubMedCrossRefGoogle Scholar
  3. 3.
    Bourne, D. and L. Dittert (1995). Pharmacokinetics. Modern Pharmaceutics. G. Banker and C. Rhodes. New York, NY, Marcel Dekker.Google Scholar
  4. 4.
    Double, J. A. and M. C. Bibby (1989). “Therapeutic index: A vital component in selection of anticancer agents for clinical trial.” Journal of the National Cancer Institute 81(13): 988–994.PubMedCrossRefGoogle Scholar
  5. 5.
    Hann, B. and A. Balmain (2001). “Building ‘validated' mouse models of human cancer.” Current Opinion in Cell Biology 13(6): 778–784.PubMedCrossRefGoogle Scholar
  6. 6.
    Corbett, T. H., L. Polin, et al. (2002). Transplantable syngeneic rodent tumors: solid tumors in mice. Tumor Models in Cancer Research,. T. B. A. Totowa, NJ., Humana Press.Google Scholar
  7. 7.
    Averbook, B. J., J. L. Schuh, et al. (2002). “Antitumor Effects of Flt3 Ligand in Transplanted Murine Tumor Models.” Journal of Immunotherapy 25: 27–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Fiebig, H. and A. Burger (2002). Human tumor xenografts and explants. Tumor Models in Cancer Research. B. A. Teicher. Totowa, NY, Humana Press Inc: 113–137.Google Scholar
  9. 9.
    Kaitin, K. (Ed.) (2007). “Despite more cancer drugs in R&D, overall U.S. approval rate is 8%.” Tufts Center for the Study of Drug Development Impact Report 9(5).Google Scholar
  10. 10.
    Longley, D. and P. Johnston (2005). “Molecular mechanisms of drug resistance.” Journal of Pathology 205: 275–92.PubMedCrossRefGoogle Scholar
  11. 11.
    Leonessa, F. and R. Clarke (2003). “ATP binding cassette transporters and drug resistance in breast cancer.” Endocrine-Related Cancer 10(1): 43–73.PubMedCrossRefGoogle Scholar
  12. 12.
    Jordan, M., H. Miller, et al. (2006). “The Pat-21 breast cancer model derived from a patient with primary Taxol® resistance recapitulates the phenotype of its origin, has altered beta-tubulin expression and is sensitive to ixabepilone.” Proceedings of the American Association for Cancer Research 97th Annual Meeting: LB-280.Google Scholar
  13. 13.
    Höfle, G., N. Bedorf, et al. (1996). “Epothilone A and B – novel 16-membered macrolides and cytotoxic activity: Isolation, crystal structure, and conformation in solution.” Angewandte Chemie (International ed. in English) 35: 1567–1569.Google Scholar
  14. 14.
    Sawyers, C. L. (1999). “Chronic myeloid leukemia.” N Engl J Med 340: 1330–1340.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Francis Lee
    • 1
  • Roberto Weinmann
  1. 1.Bristol-Myers Squibb Research and Development, Oncology DiscoveryPrincetonUSA

Personalised recommendations